


Intellectual Property (Non-confidential)



NATIONAL MEDICAL CENTER AND
BECKMAN RESEARCH INSTITUTE

Small Molecule Therapeutics for Complications of Diabetes



DESCRIPTION

The formation of advanced glycation end products (AGEs) has been identified as the major pathogenic link between hyperglycemia and the long-term complications of diabetes. This technology is a novel library of molecules that can be used to treat these complications of diabetes as well as renal dysfunction, hyperlipidaemia, atherosclerosis and overall oxidative stress. These molecules function by interfering with reactive carbonyl species formation and free radical production. Research is continuing on new therapeutic applications for these molecules.

KEY ASPECTS

- There is *in vivo* data available
- IP is available on both the composition of the molecules and their methods of use

PUBLISHED DATA

- Figarola JL, Loera S, Weng Y, Shanmugam N, Natarajan R, Rahbar S. LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat. *Diabetologia*. 2008 May;51(5):882-91.
- Rahbar S. Novel inhibitors of glycation and AGE formation. *Cell Biochem Biophys*. 2007;48(2-3):147-57.

INTELLECTUAL PROPERTY*

Title	US Patent Number	Issued
Methods of Lowering Lipid Levels in a Mammal	7,652,037	1/26/2010
Methods of Lowering Lipid Levels in a Mammal	7,320,988	1/22/2008
Novel Inhibitors of Formation of Advanced Glycation Endproducts	7,030,133	4/18/2006
Novel Inhibitors of Formation of Advanced Glycation Endproducts	6,787,566	9/7/2004
Pentoxifylline, Pioglitazone and Metformin are inhibitors of Formation of Advanced Glycation Endproducts (AGE's)	6,693,106	2/17/2004
Inhibitors of Formation of Advanced Glycation Endproducts (AGE's)	6,605,642	8/12/2003
Novel Breakers of Advanced Glycation Endproducts	6,589,944	7/8/2003

*There are additional pending domestic applications and additional pending or issued foreign equivalents.

CONTACT

Matthew Grunseth, M.B.S.
Manager, Office of Technology Licensing
Telephone: (626) 471-7221 | Email: mgrunseth@coh.org

This material is a summary of public domain and non-confidential City of Hope information. Additional material may be disclosed under a confidentiality agreement.